中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
N-{[(2-甲基-2-丙基)氧基]羰基}苯丙氨酰亮氨酸甲酯 | methyl (S)-2-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido)-4-methylpentanoate | 64152-76-7 | C21H32N2O5 | 392.495 |
—— | N-tert-butyloxycarbonyl-L-phenylalanyl-L-leucine benzyl ester | 74193-68-3 | C27H36N2O5 | 468.593 |
L-苯丙氨酰-L-亮氨酸 | L-Phe-Leu | 3303-55-7 | C15H22N2O3 | 278.351 |
BOC-L-苯丙氨酸 | N-tert-butoxycarbonyl-L-phenylalanine | 13734-34-4 | C14H19NO4 | 265.309 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | tert-butyl (S)-1-((S)-1-hydroxy-4-methylpentan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate | 78452-02-5 | C20H32N2O4 | 364.485 |
—— | tert-butyl ((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate | 74257-73-1 | C20H31N3O4 | 377.484 |
—— | N-[1-(cyclohexylmethyl)-2-hydroxypropyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | —— | C30H49N3O5 | 531.736 |
—— | Boc-Phe-Leu-Phe-OMe | 111532-44-6 | C30H41N3O6 | 539.672 |
—— | (S*,R*)-N-[1-(cyclohexylmethyl)-2-hydroxy-3-oxohexyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | —— | C33H53N3O6 | 587.8 |
—— | N-[1-(cyclohexylmethyl)-3,3,3-trifluoro-2-hydroxypropyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | 120586-95-0 | C30H46F3N3O5 | 585.708 |
—— | (R*)-N-[1-(cyclohexylmethyl)-2,3-dioxohexyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | —— | C33H51N3O6 | 585.784 |
—— | (1-{1-[1-Cyclohexylmethyl-2-hydroxy-4-(3-methyl-butylcarbamoyl)-pent-4-enylcarbamoyl]-3-methyl-butylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester | 110613-43-9 | C38H62N4O6 | 670.933 |
L-苯丙氨酰-L-亮氨酸 | L-Phe-Leu | 3303-55-7 | C15H22N2O3 | 278.351 |
—— | N-[1-(cyclohexylmethyl)-3,3,3-trifluoro-2-oxopropyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | 120586-96-1 | C30H44F3N3O5 | 583.692 |
—— | 6-O-(N-tert-butyloxycarbonyl-L-phenylalanyl-L-leucyl)-D-glucopyranose | 126369-79-7 | C26H40N2O10 | 540.611 |
—— | N-[1-(cyclohexylmethyl)-3-ethoxy-2,3-dioxopropyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | 169529-75-3 | C32H49N3O7 | 587.757 |
—— | ((S)-1-{(S)-1-[(1S,2R)-1-Cyclohexylmethyl-2-hydroxy-3-(propane-2-sulfonyl)-propylcarbamoyl]-3-methyl-butylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester | 110205-84-0 | C33H55N3O7S | 637.882 |
—— | (2R,3S)-methyl <3-<<<(tert-butyloxycarbonyl)phenylalaninyl>leucyl>amino>-4-cyclohexyl-2-hydroxybutyl>phosphonate | 123381-47-5 | C31H52N3O8P | 625.743 |
—— | (2R,3S)-dimethyl <3-<<<(tert-butyloxycarbonyl)phenylalaninyl>leucyl>amino>-4-cyclohexyl-2-hydroxybutyl>phosphonate | 123381-46-4 | C32H54N3O8P | 639.77 |
—— | Tyr-D-Ser(O-t-Bu)-Gly-Phe-Leu-Thr | 111035-56-4 | C37H54N6O10 | 742.87 |
—— | 2- |
136860-05-4 | C26H41N3O9 | 539.626 |
—— | (S*,R*)-N-[1-(cyclohexylmethyl)-2-hydroxy-2-(2-propyl-1,3-dithian-2-yl)ethyl]-N2-{N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl}-L-leucinamide | —— | C36H59N3O5S2 | 678.014 |
—— | (1S,2S)-N-<1-(cyclohexylmethyl)-2-(dimethoxyphosphinyl)-2-hydroxyethyl>-N2- |
131434-98-5 | C31H52N3O8P | 625.743 |
—— | N- |
136860-06-5 | C26H41N3O9 | 539.626 |
—— | (1S,2S)-N-<1-(cyclohexylmethyl)-2-(diethoxyphosphinyl)-2-hydroxyethyl>-N2- |
169529-76-4 | C33H56N3O8P | 653.797 |
—— | (1S,2R)-N-<1-(cyclohexylmethyl)-2-(diethoxyphosphinyl)-2-hydroxyethyl>-N2- |
—— | C33H56N3O8P | 653.797 |
—— | (2S)-N-[(3-bromophenyl)methyl]-4-methyl-2-[[(2S)-3-phenyl-2-(prop-2-enoylamino)propanoyl]amino]pentanamide | 862839-09-6 | C25H30BrN3O3 | 500.435 |
—— | benzyl 6- |
136860-04-3 | C33H47N3O9 | 629.751 |
—— | cyclo(-Leu-Ser-Phe-Leu-Pro-Val-Asn-) | 25428-71-1 | C38H58N8O9 | 770.927 |
—— | (1S,2S)-N-<1-(cyclohexylmethyl)-2-(diethoxyphosphinyl)-2-hydroxyethyl>-N2- |
—— | C34H56N3O7P | 649.808 |
Misfolding and aggregation of cellular prion protein is associated with a large array of neurological disorders commonly called the transmissible spongiform encephalopathies. Designing inhibitors against prions has remained a daunting task owing to limited information about mechanism(s) of their pathogenic self-assembly. Here, we explore the anti-prion properties of a combinatorial library of bispidine-based peptidomimetics (BPMs) that conjugate amino acids with hydrophobic and aromatic side chains. Keeping the bispidine unit unaltered, a series of structurally diverse BPMs were synthesized and tested for their prion-modulating properties. Administration of Leu- and Trp-BPMs delayed and completely inhibited the amyloidogenic conversion of human prion protein (HuPrP), respectively. We found that each BPM induced the HuPrP to form unique oligomeric nanostructures differing in their biophysical properties, cellular toxicities and response to conformation-specific antibodies. While Leu-BPMs were found to stabilize the oligomers, Trp-BPMs effected transient oligomerization, resulting in the formation of non-toxic, non-fibrillar aggregates. Yet another aromatic residue, Phe, however, accelerated the aggregation process in HuPrP. Molecular insights obtained through MD (molecular dynamics) simulations suggested that each BPM differently engages a conserved Tyr 169 residue at the α2–β2 loop of HuPrP and affects the stability of α2 and α3 helices. Our results demonstrate that this new class of molecules having chemical scaffolds conjugating hydrophobic/aromatic residues could effectively modulate prion aggregation and toxicity.